Hepion Pharmaceuticals

Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for liver diseases caused by non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infections (HBV, HCV, HDV). The company's lead candidate drug, CRV431, reduced liver fibrosis and the tumor burden of hepatocellular carcinoma in NASH experimental models. Preclinical studies have also confirmed antiviral activity against HBV, HCV, and HDV through multiple mechanisms.On July 22, 2019, ContraVir Pharmaceuticals, Inc. announced its official name change to Hepion Pharmaceuticals, Inc., along with a change in stock trading symbol from "CTRV" to "HEPA".